Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients
- Registration Number
- NCT00929539
- Lead Sponsor
- Akros Pharma Inc.
- Brief Summary
The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 496
Inclusion Criteria
- Have type 2 diabetes;
- Body mass index (BMI) of > 27.0 kg/m2 and ≤ 45.0 kg/m2;
- Are either drug naïve with respect to hypoglycemic agents OR are currently being treated with metformin alone or in combination with a sulfonylurea. Metformin and sulfonylurea dosing must be stable.
Exclusion Criteria
- Females who are pregnant or breast-feeding
- Known medical history or presence of type 1 diabetes, pancreatitis, unstable or rapidly progressing retinopathy, nephropathy or neuropathy;
- Acute coronary syndrome or uncontrolled hypertension;
- Does not meet medication restriction criteria, as described in the protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dose 1 JTT-130 JTT-130 - Placebo JTT-130 Placebo - Dose 2 JTT-130 JTT-130 - Dose 3 JTT-130 JTT-130 -
- Primary Outcome Measures
Name Time Method Change in glycosylated hemoglobin (HbA1c) levels End of Study
- Secondary Outcome Measures
Name Time Method Safety and tolerability data End of Study
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie JTT-130's efficacy in obese Type 2 diabetic patients?
How does JTT-130 compare to metformin and sulfonylureas in glycemic control for treatment-naïve Type 2 diabetes?
Which biomarkers correlate with improved HbA1c outcomes in JTT-130-treated obese Type 2 diabetic patients?
What are the most common adverse events reported in Phase II trials of JTT-130 for Type 2 diabetes?
What combination therapies with JTT-130 are being explored for Type 2 Diabetes Mellitus by Akros Pharma Inc.?